A detailed history of Washington Trust Advisors, Inc. transactions in Greenwich Life Sciences, Inc. stock. As of the latest transaction made, Washington Trust Advisors, Inc. holds 200 shares of GLSI stock, worth $2,442. This represents 0.0% of its overall portfolio holdings.

Number of Shares
200
Previous 200 -0.0%
Holding current value
$2,442
Previous $3,000 33.33%
% of portfolio
0.0%
Previous 0.0%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Jan 18, 2024

BUY
$7.77 - $12.3 $1,554 - $2,460
200 New
200 $2,000

Others Institutions Holding GLSI

About Greenwich LifeSciences, Inc.


  • Ticker GLSI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 12,848,200
  • Market Cap $157M
  • Description
  • Greenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent breast cancer recurrences in patients who ha...
More about GLSI
Track This Portfolio

Track Washington Trust Advisors, Inc. Portfolio

Follow Washington Trust Advisors, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Washington Trust Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Washington Trust Advisors, Inc. with notifications on news.